Inhibikase Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Inhibikase executed a 1-for-6 reverse stock split effective June 30, 2023 (stockholder-approved June 23, 2023; board approved June 26, 2023) to meet Nasdaq Capital Market minimum bid requirement. On January 3, 2025, the company increased authorized common shares from 100M to 500M (total authorized stock from 110M to 510M shares). On June 26, 2026, Article IX was amended to extend officer liability protection equivalent to director protections under Delaware law. Additionally, the 2020 Equity Incentive Plan was amended to set aggregate Plan Limit at 41,386,723 shares with 4% annual increases (capped at 7,532,534 shares), and non-employee director compensation policy adopted June 11, 2026 set maximum annual compensation at $750,000 per director.
Why this rating
Routine corporate governance amendments. Reverse split is standard compliance action; 5x share authorization increase is typical dilution buffer; officer indemnity is standard Delaware practice; equity plan refresh is administrative. No material business change.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.